TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomized Controlled Trial to Evaluate the Effect of Infant Formula on the Resolution of Cow's Milk Allergy of Infancy
Brief Summary: Primary Endpoint

-The percentage of subjects who develop tolerance to cow's milk protein by 12 months post randomization to study formula.

Secondary Endpoints

* Tolerance

  * The transcriptional profile of milk-specific T cells by clinical outcome.
  * Growth and Weight Velocity
  * Stool Consistency and Frequency
  * The estimated frequency of milk-specific T cells by clinical outcome.
  * The TCR diversity of milk-specific T cells by clinical outcome.
  * The milk allergen component-specific IgE, IgG4 and IgA by clinical outcome.
* Safety

  * The rate of reported adverse events by treatment group.


Options:
A: Arm Label: Control Study Formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Control Study Formula | Arm Label: Experimental Study Formula; Type: EXPERIMENTAL; Interventions: Other: Experimental Study Formula | Intervention Type: OTHER; Name: Control Study Formula; Assigned to Arm(s): Control Study Formula | Intervention Type: OTHER; Name: Experimental Study Formula; Assigned to Arm(s): Experimental Study Formula
B: Arm Label: Amix; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Amix | Intervention Type: DIETARY_SUPPLEMENT; Name: Amix; Assigned to Arm(s): Amix
C: Arm Label: Amino Acid Formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Amino Acid Formula | Arm Label: EHCF; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Extensively Hydrolyzed Casein Formula | Arm Label: EHCF + LGG; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lactobacillus GG, Dietary Supplement: Extensively Hydrolyzed Casein Formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus GG; Assigned to Arm(s): EHCF + LGG | Intervention Type: DIETARY_SUPPLEMENT; Name: Extensively Hydrolyzed Casein Formula; Assigned to Arm(s): EHCF, EHCF + LGG | Intervention Type: DIETARY_SUPPLEMENT; Name: Amino Acid Formula; Assigned to Arm(s): Amino Acid Formula
D: Arm Label: Experimental Infant Formula; Type: EXPERIMENTAL; Interventions: Other: Experimental Infant Formula | Intervention Type: OTHER; Name: Experimental Infant Formula; Assigned to Arm(s): Experimental Infant Formula

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Triggered Palliative Care for Advanced Dementia
Brief Summary: The objective of this study is to generate preliminary data for a large multi-site randomized clinical trial of a model of palliative care consultation for patients with advanced dementia, and for their family caregivers.


Options:
A: Arm Label: Specialty Palliative Care; Type: EXPERIMENTAL; Interventions: Behavioral: Specialty Palliative Care | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Specialty Palliative Care; Assigned to Arm(s): Specialty Palliative Care
B: Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: Assigned to palliative care team; Type: EXPERIMENTAL; Interventions: Behavioral: Assigned to palliative care team | Intervention Type: BEHAVIORAL; Name: Assigned to palliative care team; Assigned to Arm(s): Assigned to palliative care team | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual care
C: Arm Label: Clinicians with MI coaching; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational Interviewing | Arm Label: Wait-list control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Wait-list control | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): Clinicians with MI coaching | Intervention Type: BEHAVIORAL; Name: Wait-list control; Assigned to Arm(s): Wait-list control
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Communication training and coaching | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Communication training and coaching; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Triggered Palliative Care for Advanced Dementia
Brief Summary: The objective of this study is to generate preliminary data for a large multi-site randomized clinical trial of a model of palliative care consultation for patients with advanced dementia, and for their family caregivers.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Memantine ER; Type: ACTIVE_COMPARATOR; Interventions: Drug: memantine ER | Intervention Type: DRUG; Name: memantine ER; Assigned to Arm(s): Memantine ER | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Specialty Palliative Care; Type: EXPERIMENTAL; Interventions: Behavioral: Specialty Palliative Care | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Specialty Palliative Care; Assigned to Arm(s): Specialty Palliative Care
C: Arm Label: ACP Video Program; Type: EXPERIMENTAL; Interventions: Behavioral: ACP Video Program | Arm Label: Usual ACP procedures; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ACP Video Program; Assigned to Arm(s): ACP Video Program
D: Arm Label: Decision support; Type: EXPERIMENTAL; Interventions: Other: Feeding Options in Dementia Decision Aid | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Feeding Options in Dementia Decision Aid; Assigned to Arm(s): Decision support

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Hazardous Alcohol Use & Human Immunodeficiency Virus (HIV) Viral Load: A Randomized Controlled Trial (RCT) in Antiretroviral Therapy (ART) Clinics in Vietnam
Brief Summary: The purpose of this study is to compare the effectiveness of two interventions \[a Brief Intervention (BI) and a Motivational Enhancement Therapy+Cognitive Behavioral Therapy (MET+CBT) Intervention\], against each other and with an assessment-only control, in improving both alcohol- and HIV-related outcomes, among hazardous and heavy drinking HIV-infected antiretroviral therapy (ART) clinic clients in Thai Nguyen, Vietnam.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Intervention for Alcohol Use | Intervention Type: BEHAVIORAL; Name: Behavioral Intervention for Alcohol Use; Assigned to Arm(s): Intervention
B: Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Other: Observation | Arm Label: Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Other: ASSIST-linked brief intervention for hazardous and harmful substance use. | Intervention Type: OTHER; Name: ASSIST-linked brief intervention for hazardous and harmful substance use.; Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: Observation; Assigned to Arm(s): Control group
C: Arm Label: Brief Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Intervention | Arm Label: MET+CBT Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Enhancement Therapy (MET) Intervention, Behavioral: Cognitive Behavioral Therapy (CBT) Intervention | Arm Label: Assessment-Only Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brief Intervention; Assigned to Arm(s): Brief Intervention | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement Therapy (MET) Intervention; Assigned to Arm(s): MET+CBT Intervention | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT) Intervention; Assigned to Arm(s): MET+CBT Intervention
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Escalating incentives (EtG tests); Type: EXPERIMENTAL; Interventions: Behavioral: Incentives for negative EtG test | Arm Label: Escalating incentives (IsoScreen tests); Type: EXPERIMENTAL; Interventions: Behavioral: Incentives for positive IsoScreen test | Arm Label: Escalating incentives (EtG + IsoScreen); Type: EXPERIMENTAL; Interventions: Behavioral: Incentives for negative EtG test, Behavioral: Incentives for positive IsoScreen test | Intervention Type: BEHAVIORAL; Name: Incentives for negative EtG test; Assigned to Arm(s): Escalating incentives (EtG + IsoScreen), Escalating incentives (EtG tests) | Intervention Type: BEHAVIORAL; Name: Incentives for positive IsoScreen test; Assigned to Arm(s): Escalating incentives (EtG + IsoScreen), Escalating incentives (IsoScreen tests)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Determinants of Olfactory Dysfunction in Chronic Rhinosinusitis
Brief Summary: Olfactory dysfunction is a cardinal symptom of chronic rhinosinusitis, a disease which affects 12.5% of the adult population across all racial and ethnic groups. Previous research has documented olfactory deficit in 68% of patients with chronic rhinosinusitis and 20% with complete anosmia, suggesting that olfactory dysfunction affects over 25 million individuals in the United States with chronic rhinosinusitis. This proposed investigation will be used to predict olfactory outcomes following treatments for chronic rhinosinusitis and gain insights into mechanisms of olfactory dysfunction in this population.


Options:
A: Arm Label: Insulin fast dissolving film; Type: EXPERIMENTAL; Interventions: Combination Product: Insulin film, Device: Fast dissolving film | Arm Label: Plain fast dissolving film; Type: PLACEBO_COMPARATOR; Interventions: Combination Product: Insulin film, Device: Fast dissolving film | Intervention Type: COMBINATION_PRODUCT; Name: Insulin film; Assigned to Arm(s): Insulin fast dissolving film, Plain fast dissolving film | Intervention Type: DEVICE; Name: Fast dissolving film; Assigned to Arm(s): Insulin fast dissolving film, Plain fast dissolving film
B: Arm Label: Ascorbic Acid; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Ascorbic Acid | Arm Label: Zinc Gluconate; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Zinc Gluconate | Arm Label: Ascorbic Acid and Zinc Gluconate; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Ascorbic Acid and Zinc Gluconate | Arm Label: Standard of Care; Type: OTHER; Interventions: Other: Standard of Care | Intervention Type: DIETARY_SUPPLEMENT; Name: Ascorbic Acid; Assigned to Arm(s): Ascorbic Acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc Gluconate; Assigned to Arm(s): Zinc Gluconate | Intervention Type: DIETARY_SUPPLEMENT; Name: Ascorbic Acid and Zinc Gluconate; Assigned to Arm(s): Ascorbic Acid and Zinc Gluconate | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Standard of Care
C: Arm Label: mometasone nasal spray; Type: EXPERIMENTAL; Interventions: Drug: mometasone furoate nasal spray | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: mometasone furoate nasal spray; Assigned to Arm(s): mometasone nasal spray
D: Arm Label: Appropriate Medical Therapy; Type: N/A; Interventions: N/A | Arm Label: Endoscopic Sinus Surgery; Type: N/A; Interventions: Procedure: Endoscopic sinus surgery | Intervention Type: PROCEDURE; Name: Endoscopic sinus surgery; Assigned to Arm(s): Endoscopic Sinus Surgery

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Determinants of Olfactory Dysfunction in Chronic Rhinosinusitis
Brief Summary: Olfactory dysfunction is a cardinal symptom of chronic rhinosinusitis, a disease which affects 12.5% of the adult population across all racial and ethnic groups. Previous research has documented olfactory deficit in 68% of patients with chronic rhinosinusitis and 20% with complete anosmia, suggesting that olfactory dysfunction affects over 25 million individuals in the United States with chronic rhinosinusitis. This proposed investigation will be used to predict olfactory outcomes following treatments for chronic rhinosinusitis and gain insights into mechanisms of olfactory dysfunction in this population.


Options:
A: Arm Label: Omega-3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega-3 Fatty Acid Supplement | Arm Label: Placebo/Control; Type: SHAM_COMPARATOR; Interventions: Drug: Placebo/Control | Intervention Type: DRUG; Name: Omega-3 Fatty Acid Supplement; Assigned to Arm(s): Omega-3 | Intervention Type: DRUG; Name: Placebo/Control; Assigned to Arm(s): Placebo/Control
B: Arm Label: Appropriate Medical Therapy; Type: N/A; Interventions: N/A | Arm Label: Endoscopic Sinus Surgery; Type: N/A; Interventions: Procedure: Endoscopic sinus surgery | Intervention Type: PROCEDURE; Name: Endoscopic sinus surgery; Assigned to Arm(s): Endoscopic Sinus Surgery
C: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Drug: Budesonide Nasal | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Other: Physiological serum | Intervention Type: DRUG; Name: Budesonide Nasal; Assigned to Arm(s): Experimental group | Intervention Type: OTHER; Name: Physiological serum; Assigned to Arm(s): Control group
D: Arm Label: mometasone nasal spray; Type: EXPERIMENTAL; Interventions: Drug: mometasone furoate nasal spray | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: mometasone furoate nasal spray; Assigned to Arm(s): mometasone nasal spray

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Determinants of Olfactory Dysfunction in Chronic Rhinosinusitis
Brief Summary: Olfactory dysfunction is a cardinal symptom of chronic rhinosinusitis, a disease which affects 12.5% of the adult population across all racial and ethnic groups. Previous research has documented olfactory deficit in 68% of patients with chronic rhinosinusitis and 20% with complete anosmia, suggesting that olfactory dysfunction affects over 25 million individuals in the United States with chronic rhinosinusitis. This proposed investigation will be used to predict olfactory outcomes following treatments for chronic rhinosinusitis and gain insights into mechanisms of olfactory dysfunction in this population.


Options:
A: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Drug: Budesonide Nasal | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Other: Physiological serum | Intervention Type: DRUG; Name: Budesonide Nasal; Assigned to Arm(s): Experimental group | Intervention Type: OTHER; Name: Physiological serum; Assigned to Arm(s): Control group
B: Arm Label: Rehabilitation therapy only (control group); Type: PLACEBO_COMPARATOR; Interventions: Procedure: Olfactory Rehab | Arm Label: Rehabilitation and treatment with PEA-LUT; Type: ACTIVE_COMPARATOR; Interventions: Combination Product: co-ultraPEALut | Arm Label: Treatment with PEA-LUT one sachet daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: PEA-LUT 1 sachet | Arm Label: Treatment with PEA-LUT two sachet daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: PEA-LUT 2 sachet day | Intervention Type: COMBINATION_PRODUCT; Name: co-ultraPEALut; Assigned to Arm(s): Rehabilitation and treatment with PEA-LUT | Intervention Type: PROCEDURE; Name: Olfactory Rehab; Assigned to Arm(s): Rehabilitation therapy only (control group) | Intervention Type: DRUG; Name: PEA-LUT 1 sachet; Assigned to Arm(s): Treatment with PEA-LUT one sachet daily | Intervention Type: DRUG; Name: PEA-LUT 2 sachet day; Assigned to Arm(s): Treatment with PEA-LUT two sachet daily
C: Arm Label: Appropriate Medical Therapy; Type: N/A; Interventions: N/A | Arm Label: Endoscopic Sinus Surgery; Type: N/A; Interventions: Procedure: Endoscopic sinus surgery | Intervention Type: PROCEDURE; Name: Endoscopic sinus surgery; Assigned to Arm(s): Endoscopic Sinus Surgery
D: Arm Label: Local Nasal Steroid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ophtamesone | Arm Label: Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ophtamesone | Intervention Type: DRUG; Name: Ophtamesone; Assigned to Arm(s): Local Nasal Steroid, Normal Saline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Determinants of Olfactory Dysfunction in Chronic Rhinosinusitis
Brief Summary: Olfactory dysfunction is a cardinal symptom of chronic rhinosinusitis, a disease which affects 12.5% of the adult population across all racial and ethnic groups. Previous research has documented olfactory deficit in 68% of patients with chronic rhinosinusitis and 20% with complete anosmia, suggesting that olfactory dysfunction affects over 25 million individuals in the United States with chronic rhinosinusitis. This proposed investigation will be used to predict olfactory outcomes following treatments for chronic rhinosinusitis and gain insights into mechanisms of olfactory dysfunction in this population.


Options:
A: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Drug: Budesonide Nasal | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Other: Physiological serum | Intervention Type: DRUG; Name: Budesonide Nasal; Assigned to Arm(s): Experimental group | Intervention Type: OTHER; Name: Physiological serum; Assigned to Arm(s): Control group
B: Arm Label: mometasone nasal spray; Type: EXPERIMENTAL; Interventions: Drug: mometasone furoate nasal spray | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: mometasone furoate nasal spray; Assigned to Arm(s): mometasone nasal spray
C: Arm Label: Insulin fast dissolving film; Type: EXPERIMENTAL; Interventions: Combination Product: Insulin film, Device: Fast dissolving film | Arm Label: Plain fast dissolving film; Type: PLACEBO_COMPARATOR; Interventions: Combination Product: Insulin film, Device: Fast dissolving film | Intervention Type: COMBINATION_PRODUCT; Name: Insulin film; Assigned to Arm(s): Insulin fast dissolving film, Plain fast dissolving film | Intervention Type: DEVICE; Name: Fast dissolving film; Assigned to Arm(s): Insulin fast dissolving film, Plain fast dissolving film
D: Arm Label: Appropriate Medical Therapy; Type: N/A; Interventions: N/A | Arm Label: Endoscopic Sinus Surgery; Type: N/A; Interventions: Procedure: Endoscopic sinus surgery | Intervention Type: PROCEDURE; Name: Endoscopic sinus surgery; Assigned to Arm(s): Endoscopic Sinus Surgery

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Measuring and Understanding the Effects of a Performance Based Financing Scheme Applied to Nutrition Services in Burundi
Brief Summary: The government of Burundi is implementing a new financing scheme in health centres. The objective is to provide additional financial compensations to health centres on the basis of their performance in nutrition activities: it consists in the introduction of criteria focusing on malnutrition prevention and care activities in the existing performance based financing (PBF) system.

The general objective of this study is to assess the effects of this new financing scheme, to document its impact and to study the chains through which it occurred. This study will provide key evidence for countries with an existing PBF scheme and confronted with malnutrition problems on the appropriateness to extend the strategy to nutrition services. If this impact evaluation brings positive results, this may have implications for the global fight against malnutrition.


Options:
A: Arm Label: Nutrition PBF; Type: EXPERIMENTAL; Interventions: Other: Nutrition PBF | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Nutrition PBF; Assigned to Arm(s): Nutrition PBF
B: Arm Label: No incentive; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: KES financial incentive 1; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentive | Arm Label: KES financial incentive 2; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentive | Arm Label: KES financial incentive 3; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentive | Arm Label: KES financial incentive 4; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentive | Intervention Type: BEHAVIORAL; Name: Financial incentive; Assigned to Arm(s): KES financial incentive 1, KES financial incentive 2, KES financial incentive 3, KES financial incentive 4
C: Intervention Type: BEHAVIORAL; Name: Guideline adherence and financial incentive; Assigned to Arm(s): N/A
D: Arm Label: Performance based incentives; Type: EXPERIMENTAL; Interventions: Behavioral: Performance based incentives | Arm Label: Comparison; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Performance based incentives; Assigned to Arm(s): Performance based incentives

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Mass Drug Administration (MDA) for Reducing Seasonal Malaria Transmission Towards Its Elimination in Hotspot Areas in Zanzibar - a Cluster-randomised Controlled Trial
Brief Summary: The overall aim of this study is to determine the effectiveness of two rounds of mass drug administration (MDA) with dihydroartemisinin-piperaquine (DHAp) + single low dose (SLD) primaquine for reducing seasonal malaria transmission in Shehias considered hotspots on Unguja Island, Zanzibar.


Options:
A: Arm Label: Participants; Type: OTHER; Interventions: Drug: Dihydroartemisinin-piperaquine | Intervention Type: DRUG; Name: Dihydroartemisinin-piperaquine; Assigned to Arm(s): Participants
B: Arm Label: MDA with DHAp and SLD Primaquine; Type: EXPERIMENTAL; Interventions: Drug: MDA with DHAp and SLD Primaquine | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: MDA with DHAp and SLD Primaquine; Assigned to Arm(s): MDA with DHAp and SLD Primaquine
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Drug: Artesunate (day 1,2,3: 4 mg/kg), Drug: Primaquine-base (day 3: 0.75 mg/kg) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artesunate (day 1,2,3: 4 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Primaquine-base (day 3: 0.75 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): 2
D: Arm Label: malaria elimination using DP and low-dose primaquine; Type: EXPERIMENTAL; Interventions: Drug: malaria elimination using DP and low-dose primaquine | Arm Label: Control villages; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: malaria elimination using DP and low-dose primaquine; Assigned to Arm(s): malaria elimination using DP and low-dose primaquine

Answer: B